Breaks Categories: News

WednesdayJan 06, 2021 8:30 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering from OSA around the world, it is the most predominant diseases, and can cause life-threatening high blood pressure, heart failure, stroke and other health problems. and life-threatening diseases. “We believe that Vivos’ sleep-specific AireO2 patient…

Continue Reading

TuesdayJan 05, 2021 11:30 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to investors, financial and industry analysts, registered brokers and financial writers. Those introductions would be made with the intent to provide interested individuals and groups with information about POAI’s business strategy, developments and accomplishments. The announcement also noted that Landon Capital would assist POAI in the…

Continue Reading

TuesdayJan 05, 2021 10:39 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters into Agreement with Fortune 500 Subsidiary to Provide Digital Therapeutics Solution

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has been selected by a subsidiary of a U.S.-based Fortune 500 technology and engineering company to provide its digital therapeutics solution to eligible employees. DarioHealth’s partnership with Vitality Group made this agreement possible, which is DarioHealth’s first client in the self-insured employer market. One of the largest wellness companies in the world, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and their organizations; an estimated 20 million people in 26 markets engage in the Vitality program. Under the announced agreement, members…

Continue Reading

TuesdayJan 05, 2021 10:05 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a summary of the company’s business and clinical-development programs to any interested parties. His presentation will also include expected 2021 highlights. In addition, Sapirstein will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies. The multiday event is scheduled for Jan. 6–8 and 11–14, 2021. To register for the event, visit https://ibn.fm/JBmMH To view the full press release, visit…

Continue Reading

MondayJan 04, 2021 2:02 pm

BioMedNewsBreaks – Retractable Technologies Inc. (NYSE: RVP) Named ‘2020’s Stock of the Year’ by The Bowser Report

Retractable (NYSE: RVP), a manufacturer and marketer of safety syringes and other innovative medical products for the health care industry, was recognized as the “Stock of the Year” for 2020 by The Bowser Report LLC. The report reads, “Unlike last year’s top pick [Repro Med Systems Inc. (NASDAQ: KRMD)], Retractable Technologies is a recent addition to the newsletter, named Company of the Month in January 2020. At the time, RVP was trading at $1.48. Just a couple of months after recommendation, the world and financial markets were shocked by the COVID-19 pandemic, which forced lockdowns, quarantines and stay-at-home orders. While…

Continue Reading

MondayJan 04, 2021 12:02 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Worldwide License Agreement with First Wave Bio, $8M Offerings

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (“ICI-AC”) and COVID-19 GI infections. “The acquisition of rights to niclosamide for these indications gives us an opportunity to strategically expand our existing pipeline and pursue multiple GI indications in the oncology and infectious disease arenas,” said James Sapirstein, president and CEO of AzurRx. “We are…

Continue Reading

WednesdayDec 30, 2020 11:09 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. The article covers the proposed mechanism of action of VistaGen’s investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders.* The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B…

Continue Reading

WednesdayDec 30, 2020 10:52 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Commences FDA EUA Study for POC COVID-19 Testing

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

Continue Reading

WednesdayDec 30, 2020 9:58 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders

Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required quorum had still not been reached, with only 47% of the outstanding shares having been voted. In cancelling the meeting, the Board of Directors for POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, noted that it was…

Continue Reading

MondayDec 28, 2020 11:39 am

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Significant Growing Interest in Its my-Cam and my-Cardia Solutions

CB Scientific (OTC: CBSC), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced the addition of dozens of new clinical trials of its my-Cam device and new hospital monitoring contracts through the company’s exclusive authorized distributor, Mango Wellness Co. Ltd. (“MWC”) and My Cardia Thailand Co. Ltd. (“MCT”) in Thailand. According to the update, MWC’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest. More…

Continue Reading